Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.64
BMY's Cash to Debt is ranked lower than
71% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. BMY: 0.64 )
Ranked among companies with meaningful Cash to Debt only.
BMY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.83 Max: 2.26
Current: 0.64
0.32
2.26
Equity to Asset 0.45
BMY's Equity to Asset is ranked lower than
74% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BMY: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
BMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.45 Max: 0.55
Current: 0.45
0.33
0.55
Interest Coverage 10.66
BMY's Interest Coverage is ranked lower than
64% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.94 vs. BMY: 10.66 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 4.67  Med: 12.82 Max: 45.04
Current: 10.66
4.67
45.04
F-Score: 4
Z-Score: 6.46
M-Score: -1.90
WACC vs ROIC
9.49%
5.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 11.09
BMY's Operating margin (%) is ranked higher than
58% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. BMY: 11.09 )
Ranked among companies with meaningful Operating margin (%) only.
BMY' s Operating margin (%) Range Over the Past 10 Years
Min: 11.41  Med: 18.21 Max: 30.74
Current: 11.09
11.41
30.74
Net-margin (%) 9.31
BMY's Net-margin (%) is ranked higher than
62% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. BMY: 9.31 )
Ranked among companies with meaningful Net-margin (%) only.
BMY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.19  Med: 14.13 Max: 56.42
Current: 9.31
9.19
56.42
ROE (%) 10.58
BMY's ROE (%) is ranked higher than
63% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. BMY: 10.58 )
Ranked among companies with meaningful ROE (%) only.
BMY' s ROE (%) Range Over the Past 10 Years
Min: 10.75  Med: 19.06 Max: 78.36
Current: 10.58
10.75
78.36
ROA (%) 4.89
BMY's ROA (%) is ranked higher than
56% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. BMY: 4.89 )
Ranked among companies with meaningful ROA (%) only.
BMY' s ROA (%) Range Over the Past 10 Years
Min: 4.78  Med: 7.63 Max: 35.08
Current: 4.89
4.78
35.08
ROC (Joel Greenblatt) (%) 51.90
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.44 vs. BMY: 51.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 45.71  Med: 56.78 Max: 155.17
Current: 51.9
45.71
155.17
Revenue Growth (3Y)(%) -1.90
BMY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. BMY: -1.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.4  Med: 2.60 Max: 7.3
Current: -1.9
-8.4
7.3
EBITDA Growth (3Y)(%) -6.10
BMY's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BMY: -6.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.6  Med: -2.40 Max: 21.5
Current: -6.1
-26.6
21.5
EPS Growth (3Y)(%) -7.10
BMY's EPS Growth (3Y)(%) is ranked lower than
71% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. BMY: -7.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: -4.80 Max: 30.7
Current: -7.1
-22.9
30.7
» BMY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

BMY Guru Trades in Q2 2015

RS Investment Management 351,060 sh (New)
Steven Cohen 849,200 sh (+36.77%)
Ken Fisher 34,636 sh (+6.77%)
Vanguard Health Care Fund 43,718,751 sh (+1.90%)
Kahn Brothers 28,800 sh (+1.41%)
T Rowe Price Equity Income Fund 5,814,800 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 211,620 sh (-0.26%)
Murray Stahl 55,867 sh (-0.27%)
Pioneer Investments 86,650 sh (-0.58%)
Mario Gabelli 678,636 sh (-3.66%)
Mairs and Power 282,983 sh (-3.67%)
Dodge & Cox 80,928 sh (-7.86%)
First Eagle Investment 13,325 sh (-8.05%)
Jeremy Grantham 7,410 sh (-8.63%)
Paul Tudor Jones 25,871 sh (-84.27%)
» More
Q3 2015

BMY Guru Trades in Q3 2015

Ray Dalio 19,528 sh (New)
John Burbank 401,253 sh (New)
George Soros 5,000 sh (New)
Joel Greenblatt 21,863 sh (New)
Signature Select Canadian Fund 258,600 sh (New)
Ken Fisher 61,180 sh (+76.64%)
RS Investment Management 522,650 sh (+48.88%)
Steven Cohen 1,099,000 sh (+29.42%)
Murray Stahl 58,442 sh (+4.61%)
Vanguard Health Care Fund 45,346,149 sh (+3.72%)
Mairs and Power 284,574 sh (+0.56%)
Pioneer Investments 86,973 sh (+0.37%)
Ronald Muhlenkamp 211,750 sh (+0.06%)
First Eagle Investment 13,325 sh (unchged)
Kahn Brothers 28,800 sh (unchged)
Steven Cohen 1,100,000 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Dodge & Cox 79,928 sh (-1.24%)
Mario Gabelli 651,417 sh (-4.01%)
T Rowe Price Equity Income Fund 5,512,700 sh (-5.20%)
Jeremy Grantham 5,400 sh (-27.13%)
Paul Tudor Jones 16,320 sh (-36.92%)
» More
Q4 2015

BMY Guru Trades in Q4 2015

Tom Gayner 10,000 sh (New)
Louis Moore Bacon 260,000 sh (New)
John Burbank 1,958,072 sh (+387.99%)
Ray Dalio 70,845 sh (+262.79%)
Pioneer Investments 215,566 sh (+147.85%)
Ken Fisher 134,800 sh (+120.33%)
Steven Cohen 1,264,200 sh (+15.03%)
Vanguard Health Care Fund 46,232,449 sh (+1.95%)
Mairs and Power 287,063 sh (+0.87%)
Ronald Muhlenkamp 211,755 sh (unchged)
Jeremy Grantham 5,400 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Samuel Isaly 1,333,000 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
RS Investment Management 521,050 sh (-0.31%)
Murray Stahl 57,542 sh (-1.54%)
Mario Gabelli 639,355 sh (-1.85%)
Jeff Auxier 4,943 sh (-1.98%)
Kahn Brothers 28,050 sh (-2.60%)
First Eagle Investment 12,943 sh (-2.87%)
Dodge & Cox 77,458 sh (-3.09%)
T Rowe Price Equity Income Fund 4,520,000 sh (-18.01%)
Paul Tudor Jones 10,400 sh (-36.27%)
» More
Q1 2016

BMY Guru Trades in Q1 2016

Ken Fisher 636,060 sh (+371.85%)
Vanguard Health Care Fund 47,754,809 sh (+3.29%)
Murray Stahl 58,876 sh (+2.32%)
First Eagle Investment 12,943 sh (unchged)
T Rowe Price Equity Income Fund 4,031,100 sh (-10.82%)
Samuel Isaly 1,029,700 sh (-22.75%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1079.030.19$2.00 Convertible Preferred Stock

Ratios

vs
industry
vs
history
P/E(ttm) 76.00
BMY's P/E(ttm) is ranked lower than
86% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. BMY: 76.00 )
Ranked among companies with meaningful P/E(ttm) only.
BMY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.05  Med: 20.42 Max: 77.45
Current: 76
4.05
77.45
Forward P/E 22.52
BMY's Forward P/E is ranked lower than
75% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.86 vs. BMY: 22.52 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 76.00
BMY's PE(NRI) is ranked lower than
86% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. BMY: 76.00 )
Ranked among companies with meaningful PE(NRI) only.
BMY' s PE(NRI) Range Over the Past 10 Years
Min: 12.26  Med: 20.92 Max: 77.61
Current: 76
12.26
77.61
P/B 8.18
BMY's P/B is ranked lower than
88% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. BMY: 8.18 )
Ranked among companies with meaningful P/B only.
BMY' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 4.14 Max: 8.38
Current: 8.18
2.46
8.38
P/S 6.98
BMY's P/S is ranked lower than
77% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. BMY: 6.98 )
Ranked among companies with meaningful P/S only.
BMY' s P/S Range Over the Past 10 Years
Min: 1.63  Med: 2.71 Max: 7.15
Current: 6.98
1.63
7.15
POCF 144.48
BMY's POCF is ranked lower than
94% of the 251 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.79 vs. BMY: 144.48 )
Ranked among companies with meaningful POCF only.
BMY' s POCF Range Over the Past 10 Years
Min: 6.96  Med: 14.66 Max: 147.61
Current: 144.48
6.96
147.61
EV-to-EBIT 48.99
BMY's EV-to-EBIT is ranked lower than
85% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.51 vs. BMY: 48.99 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 11.10 Max: 126.7
Current: 48.99
6.2
126.7
EV-to-EBITDA 43.03
BMY's EV-to-EBITDA is ranked lower than
83% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.66 vs. BMY: 43.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 9.25 Max: 57.3
Current: 43.03
5.5
57.3
Shiller P/E 34.64
BMY's Shiller P/E is ranked higher than
63% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.10 vs. BMY: 34.64 )
Ranked among companies with meaningful Shiller P/E only.
BMY' s Shiller P/E Range Over the Past 10 Years
Min: 8.99  Med: 15.14 Max: 35.38
Current: 34.64
8.99
35.38
Current Ratio 1.48
BMY's Current Ratio is ranked lower than
73% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. BMY: 1.48 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.61 Max: 2.32
Current: 1.48
1.13
2.32
Quick Ratio 1.30
BMY's Quick Ratio is ranked lower than
66% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. BMY: 1.30 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.33 Max: 2.07
Current: 1.3
0.93
2.07
Days Inventory 114.06
BMY's Days Inventory is ranked higher than
50% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. BMY: 114.06 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 122.43 Max: 141.93
Current: 114.06
84.37
141.93
Days Sales Outstanding 72.59
BMY's Days Sales Outstanding is ranked higher than
51% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.16 vs. BMY: 72.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.45 Max: 79.99
Current: 72.59
35.38
79.99
Days Payable 136.90
BMY's Days Payable is ranked higher than
80% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.22 vs. BMY: 136.90 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 78.8  Med: 141.65 Max: 230.86
Current: 136.9
78.8
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.13
BMY's Dividend Yield is ranked higher than
71% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. BMY: 2.13 )
Ranked among companies with meaningful Dividend Yield only.
BMY' s Dividend Yield Range Over the Past 10 Years
Min: 2.07  Med: 4.27 Max: 7.07
Current: 2.13
2.07
7.07
Dividend Payout 1.60
BMY's Dividend Payout is ranked lower than
97% of the 371 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. BMY: 1.60 )
Ranked among companies with meaningful Dividend Payout only.
BMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.41  Med: 0.67 Max: 37
Current: 1.6
0.41
37
Dividend Growth (3y) 2.80
BMY's Dividend Growth (3y) is ranked lower than
61% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BMY: 2.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.10 Max: 11.4
Current: 2.8
0
11.4
Forward Dividend Yield 2.15
BMY's Forward Dividend Yield is ranked higher than
66% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 2.15 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.43
BMY's Yield on cost (5-Year) is ranked higher than
63% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. BMY: 2.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.39  Med: 4.93 Max: 8.16
Current: 2.43
2.39
8.16
3-Year Average Share Buyback Ratio 0.20
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.30 vs. BMY: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0.50 Max: 5.1
Current: 0.2
-0.3
5.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.29
BMY's Price/Tangible Book is ranked lower than
95% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. BMY: 19.29 )
Ranked among companies with meaningful Price/Tangible Book only.
BMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.91  Med: 13.80 Max: 53.46
Current: 19.29
4.91
53.46
Price/Projected FCF 2.69
BMY's Price/Projected FCF is ranked higher than
50% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. BMY: 2.69 )
Ranked among companies with meaningful Price/Projected FCF only.
BMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.58 Max: 4.53
Current: 2.69
1.15
4.53
Price/Median PS Value 2.59
BMY's Price/Median PS Value is ranked lower than
88% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. BMY: 2.59 )
Ranked among companies with meaningful Price/Median PS Value only.
BMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.14 Max: 3.17
Current: 2.59
0.71
3.17
Price/Graham Number 8.07
BMY's Price/Graham Number is ranked lower than
92% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. BMY: 8.07 )
Ranked among companies with meaningful Price/Graham Number only.
BMY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.75  Med: 3.93 Max: 10.63
Current: 8.07
1.75
10.63
Earnings Yield (Greenblatt) (%) 2.02
BMY's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BMY: 2.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 9.00 Max: 16.1
Current: 2.02
0.8
16.1
Forward Rate of Return (Yacktman) (%) -14.96
BMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
85% of the 316 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. BMY: -14.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.1  Med: 6.10 Max: 26.7
Current: -14.96
-15.1
26.7

More Statistics

Revenue(Mil) $16910
EPS $ 0.93
Beta1.08
Short Percentage of Float1.29%
52-Week Range $51.82 - 73.06
Shares Outstanding(Mil)1669.31

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 18,133 20,676 22,749
EPS($) 2.51 3.14 3.94
EPS without NRI($) 2.51 3.14 3.94

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, XPAR:SAN » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.
» More Articles for NYSE:BMY

Headlines

Articles On GuruFocus.com
John Burbank Raises Stake in Microsoft Mar 02 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 Sep 14 2015 
Weekly Insider Sells Highlight: IMS, NOW, BMY, EA Aug 11 2015 
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 

More From Other Websites
Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise... May 05 2016
Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise... May 05 2016
Merck beats 1Q profit forecasts May 05 2016
Merck beats 1Q profit forecasts May 05 2016
BRISTOL MYERS SQUIBB CO Financials May 04 2016
As Google's secretive biotech spinoff ramps up, look who it's hiring May 03 2016
3 stocks set to breakout? May 02 2016
Must-See Charts: How Healthy Are Bristol-Myers, Eli Lilly, Pfizer, Merck? May 02 2016
Cramer: Raging bull market brewing for pharma Apr 28 2016
Cramer: Raging bull market brewing for pharma Apr 28 2016
Edited Transcript of BMY earnings conference call or presentation 28-Apr-16 2:30pm GMT Apr 28 2016
Bristol-Myers (BMY) Stock Climbs on Q1 Earnings, Revenue Beat Apr 28 2016
Bristol raises 2016 forecast after earnings beat Apr 28 2016
Bristol-Myers Hits 17-Year High On Q1 Report; Celgene Also Up Apr 28 2016
Here’s Why Investors Are Watching These Five Stocks Today Apr 28 2016
Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View Apr 28 2016
Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance Apr 28 2016
How Bristol-Myers Squibb (BMY) Stock Stands Out in a Strong Industry Apr 28 2016
Bristol-Myers (BMY) Beats on Q1 Earnings and Revenues Apr 28 2016
BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK